|Bid||85.95 x 800|
|Ask||86.20 x 1100|
|Day's Range||84.01 - 87.16|
|52 Week Range||33.39 - 104.53|
|Beta (3Y Monthly)||2.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||132.86|
Reata is in its 'final pivotal study' for its new drug, bardoxolone. In the trials, the drug has showed promising results to reverse kidney damage. Yahoo Finance sits down with the CEO of Reata, Warren Huff, who founded the company in 2002, to discuss the plans to launch the product in the near future.
It hasn't been the best quarter for Reata Pharmaceuticals, Inc. (NASDAQ:RETA) shareholders, since the share price has...
The government requires hedge funds and wealthy investors that crossed the $100 million equity holdings threshold are required to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the […]
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States. It is characterized by the development of pathologic fluid-filled cysts throughout the kidneys, which leads to organ enlargement and chronic kidney disease (CKD). Despite standard of care treatment, approximately 50% of these patients will progress to end-stage kidney disease and require dialysis or a kidney transplant by 60 years of age.
IRVING, Texas, June 04, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s.
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD). FALCON is an international, multi-center, randomized, double-blind, placebo-controlled trial studying the safety and efficacy of bardoxolone in approximately 300 patients with ADPKD randomized evenly to active drug or placebo.
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With.
The drug, bardoxolone, that Reata is developing to fight kidney disease has "striking efficacy," Bihua Chen says. Shares of Reata Pharmaceutical jump nearly 5% after Chen reveals her bet on the drugmaker. Bihua Chen, founder and portfolio manager at Cormorant Asset Management, said on Monday she likes Reata Pharmaceuticals RETA for the drug it's developing to fight kidney disease.
Bardoxolone methyl (bardoxolone) is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The U.S. Food and Drug Administration has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and pulmonary arterial hypertension. The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.
IRVING, Texas, May 02, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA): Reata Pharmaceuticals, Inc., a clinical stage biop...
PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019 FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019 CONFERENCE CALL WITH MANAGEMENT.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVING, Texas, Feb. 21, 2019 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results.
STATISTICALLY SIGNIFICANT IMPROVEMENT IN KIDNEY FUNCTION OBSERVED IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER 12 WEEKS OF TREATMENT BARDOXOLONE METHYL.